A new challenge for the Mexican health system: hepatitis C in people who inject drugs

Carlos Magís-Rodríguez; Rodrigo Marín-Navarrete; Ignacio García-Juárez

doi:10.17711/SM.0185-3325.2019.019

Carlos Magís-Rodríguez

Rodrigo Marín-Navarrete

Ignacio García-Juárez

DOI: https://doi.org/10.17711/SM.0185-3325.2019.019

Abstract

Injecting-drug use is present in 179 of 206 countries worldwide, with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) prevalence of 17.8% and 52.3%, respectively, among the 15.6 million people who inject drugs (PWIDs) (Degenhardt et al., 2017; Platt et al., 2016). This epidemic produces a high impact on global public health by increasing days lost associated to disability, morbidity, and mortality (Degenhardt et al., 2017).

HTML

Pdf

ePub

Issue

Vol. 42 No. 4 (2019): Salud mental

References

Comisión Nacional contra las Adicciones (CONADIC). (2017). Observatorio Mexicano de Drogas: Informe sobre consumo de drogas inyectables 2017. Retrieved from: https://www.gob.mx/salud/conadic/acciones-y-programas/observatorio-mexicano-de-drogas-omd

Degenhardt, L., Peacock, A., Colledge, S., Leung, J., Grebely, J., Vickerman, P., … Larney, S. (2017). Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. The Lancet Global Health, 5(12), e1192-e1207. doi: 10.1016/S2214-109X(17)30375-3

European Monitoring Centre for Drugs and Drug Addiction. (2018). Drug consumption rooms: an overview of provision and evidence (Perspectives on drugs). www.emcdda.europa.eu. Retrieved from: http://www.emcdda.europa.eu/publications/pods/drug-consumption-rooms_en (Access date: September 4, 2019)

Fleiz-Bautista, C., Domínguez-García, M., Villatoro-Velázquez, J. A., Vázquez-Quiroz, F., Zafra-Mora, E., Sánchez-Ramos, R., ... Medina-Mora M. E. (2019). Cuqueando la Chiva: Contextos del consumo de heroína en la frontera norte de México. Ciudad de México, México: Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz. ISBN: 978-607-98474-0-1

Horyniak, D., Wagner, K. D., Armenta, R. F., Cuevas-Mota, J., Hendrickson, E., & Garfein, R. S. (2017). Cross-border injection drug use and HIV and hepatitis C virus seropositivity among people who inject drugs in San Diego, California. International Journal of Drug Policy, 47, 9-17. doi: 10.1016/J.DRUGPO.2017.06.006

Magis-Rodríguez, C., García-Sánchez, J. A., & Marín-Navarrete, R. (2018). Harm reduction among people who inject drugs in Mexico. Salud Mental, 41(4), 153-156. doi: 10.17711/SM.0185-3325.2018.023

Nápoles, T. M., Batchelder, A. W., Lin, A., Moran, L., Johnson, M. O., Shumway, M., … Riley, E. D. (2019). HCV treatment barriers among HIV/HCV co-infected patients in the US: a qualitative study to understand low uptake among marginalized populations in the DAA era. Journal of Public Health, fdz045. doi: 10.1093/pubmed/fdz045

Noe, M. H., Grewal, S. K., Shin, D. B., Ogdie, A., Takeshita, J., & Gelfand, J. M. (2017). Increased prevalence of HCV and hepatic decompensation in adults with psoriasis: a population-based study in the United Kingdom. Journal of the European Academy of Dermatology and Venereology, 31(10), 1674-1680. doi: 10.1111/jdv.14310

Platt, L., Easterbrook, P., Gower, E., McDonald, B., Sabin, K., McGowan, C., … Vickerman, P. (2016). Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. The Lancet Infectious Diseases, 16(7), 797-808. doi: 10.1016/S1473-3099(15)00485-5

Salmon-Ceron, D., Arends, J. E., Leoni, C., Solas, C., & Peytavin, G. (2019). HIV/HCV Coinfection: Current Challenges. In: Viral Hepatitis: Chronic Hepatitis C (pp. 141-157). Cham: Springer International Publishing. doi: 10.1007/978-3-030-03757-4_7

Stancliff, S., Phillips, B. W., Maghsoudi, N., & Joseph, H. (2015). Harm reduction: Front line public health. Journal of Addictive Diseases, 34(2-3), 206-219. doi: 10.1080/10550887.2015.1059651

Valenzuela-Lara, M., Ponce-Ramos, M., Ruiz-Herrera, K., & López-González, A. (2019). Impact of funding harm reduction programs for people who inject drugs in Mexico. Salud Mental, 42(4), 157-163. doi: 10.17711/SM.0185-3325.2019.021

Wilson, D. P., Donald, B., Shattock, A. J., Wilson, D., & Fraser-Hurt, N. (2015). The cost-effectiveness of harm reduction. International Journal of Drug Policy, 26(Suppl 1), S5-S11. doi: 10.1016/J.DRUGPO.2014.11.007

Xue, W., Liu, K., Qiu, K., Shen, Y., Pan, Z., Hu, P., … Ren, H. (2019). A systematic review with meta-analysis: Is ribavirin necessary in sofosbuvir-based direct-acting antiviral therapies for patients with HCV recurrence after liver transplantation? International Journal of Infectious Diseases, 83, 56-63. doi: 10.1016/J.IJID.2019.03.038

Esta obra está bajo una Licencia Creative Commons Atribución-NoComercial 4.0 Internacional.

##plugins.themes.bootstrap3.article.main##

Abstract

References